Activation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk

Coagulation activation has been demonstrated in two prototypic autoimmune skin diseases, chronic autoimmune urticaria and bullous pemphigoid, but only the latter is associated with increased thrombotic risk. Two markers of coagulation activation (prothrombin fragment F1+2 and fibrin fragment D-dimer) were measured by immunoenzymatic methods in plasma samples from 30 patients with active chronic autoimmune urticaria, positive for autologous serum skin test, 30 patients with active bullous pemphigoid and 30 healthy subjects. In skin biopsies, tissue factor expression was evaluated by both immunohistochemistry and in situ hybridization. F1+2 and D-dimer levels were higher in active chronic autoimmune urticaria (276.5±89.8 pmol/L and 5.56±4.40 nmol/L, respectively) than in controls (145.2±38.0 pmol/L and 1.06±0.25 nmol/L; P=0.029 and P=0.011) and were much higher in active bullous pemphigoid (691.7±318.7 pmol/L and 15.24±9.09 nmol/L, respectively) (P<0.0001). Tissue factor positivity was evident in skin biopsies of both disorders with higher intensity in bullous pemphigoid. F1+2 and D-dimer, during remission, were markedly reduced in both disorders. These findings support the involvement of coagulation activation in the pathophysiology of both diseases. The strong systemic activation of coagulation in bullous pemphigoid may contribute to increase the thrombotic risk and provides the rationale for clinical trials on anticoagulant treatments in this disease.

[1]  Michihiro Hide,et al.  The EAACI/GA 2 LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update , 2015 .

[2]  J. Blalock,et al.  Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid , 2014, The Journal of investigative dermatology.

[3]  T. Zuberbier,et al.  The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. , 2014, Allergy.

[4]  R. Asero,et al.  Chronic urticaria and coagulation: pathophysiological and clinical aspects , 2014, Allergy.

[5]  J. Sheikh,et al.  The diagnosis and management of acute and chronic urticaria: 2014 update. , 2014, The Journal of allergy and clinical immunology.

[6]  M. Greaves Pathology and classification of urticaria. , 2014, Immunology and allergy clinics of North America.

[7]  S. Saini Chronic spontaneous urticaria: etiology and pathogenesis. , 2014, Immunology and allergy clinics of North America.

[8]  Enno Schmidt,et al.  Emerging treatments for pemphigoid diseases. , 2013, Trends in molecular medicine.

[9]  R. Wolf,et al.  Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. , 2013, Clinics in dermatology.

[10]  D. Zillikens,et al.  Pemphigoid diseases , 2013, The Lancet.

[11]  A. Marzano,et al.  Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease , 2013, Clinical and experimental immunology.

[12]  A. Marzano,et al.  Hypereosinophilic syndrome, Churg-Strauss syndrome and parasitic diseases: possible links between eosinophilia and thrombosis. , 2012, Current vascular pharmacology.

[13]  T. van der Poll,et al.  Crosstalk between inflammation and coagulation: the lessons of sepsis. , 2012, Current vascular pharmacology.

[14]  P. Courville,et al.  Incidence and mortality of bullous pemphigoid in France. , 2012, The Journal of investigative dermatology.

[15]  T. Dainichi,et al.  Lesional Th17 cells and regulatory T cells in bullous pemphigoid , 2011, Experimental dermatology.

[16]  D. Fanoni,et al.  Activation of coagulation in bullous pemphigoid and other eosinophil‐related inflammatory skin diseases , 2011, Clinical and experimental immunology.

[17]  Sudha Xirasagar,et al.  Increased Risk of Stroke in Patients With Bullous Pemphigoid: A Population-Based Follow-Up Study , 2011, Stroke.

[18]  A. Marzano,et al.  Plasma levels of matrix metalloproteinase‐9 in chronic urticaria patients correlate with disease severity and C‐reactive protein but not with circulating histamine‐releasing factors , 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[19]  H. Shimizu,et al.  What’s new in bullous pemphigoid , 2010, The Journal of dermatology.

[20]  F. Ingegnoli,et al.  Anti-tumour necrosis factor alpha therapy normalises fibrinolysis impairment in patients with active rheumatoid arthritis , 2010 .

[21]  P. Meroni,et al.  Skin autoimmunity and blood coagulation , 2010, Autoimmunity.

[22]  D. Fanoni,et al.  Activation of blood coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications , 2009, The British journal of dermatology.

[23]  A. Pesenti,et al.  Tight glycemic control may favor fibrinolysis in patients with sepsis* , 2009, Critical care medicine.

[24]  D. Fanoni,et al.  Expression of Tissue Factor by Eosinophils in Patients with Chronic Urticaria , 2008, International Archives of Allergy and Immunology.

[25]  R. Asero,et al.  Severe chronic urticaria is associated with elevated plasma levels of D‐dimer , 2007, Allergy.

[26]  F. Rosendaal,et al.  Venous thrombosis in the elderly , 2007, Journal of thrombosis and haemostasis : JTH.

[27]  D. Fanoni,et al.  Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. , 2007, The Journal of allergy and clinical immunology.

[28]  B. Engelmann,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use only. , 2006 .

[29]  R. Franchis,et al.  Antibodies to tissue‐type plasminogen activator (t‐PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t‐PA and possible implications in thrombosis , 2006, Journal of thrombosis and haemostasis : JTH.

[30]  R. Eming,et al.  T cell control in autoimmune bullous skin disorders. , 2006, The Journal of clinical investigation.

[31]  R. Asero,et al.  Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. , 2006, The Journal of allergy and clinical immunology.

[32]  M. Inaoki,et al.  Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases , 2006, Archives of Dermatological Research.

[33]  T. van der Poll,et al.  Two-way interactions between inflammation and coagulation. , 2005, Trends in cardiovascular medicine.

[34]  J. Roujeau,et al.  Prediction of survival for patients with bullous pemphigoid: a prospective study. , 2005, Archives of dermatology.

[35]  K. Yancey The pathophysiology of autoimmune blistering diseases. , 2005, The Journal of clinical investigation.

[36]  E. Sabo,et al.  Increased plasma levels of matrix metalloproteinase‐9 are associated with the severity of chronic urticaria , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[37]  S. Opal Phylogenetic and functional relationships between coagulation and the innate immune response. , 2000, Critical care medicine.

[38]  P. Amerio,et al.  A Th2-like Cytokine Response is Involved in Bullous Pemphigoid. The Role of IL-4 and IL-5 in the Pathogenesis of the Disease , 1999, International journal of immunopathology and pharmacology.

[39]  J. Kinet,et al.  Assessment of autoimmunity in patients with chronic urticaria. , 1997, The Journal of allergy and clinical immunology.

[40]  J. Maraganore,et al.  Thrombin functions as an inflammatory mediator through activation of its receptor , 1996, The Journal of experimental medicine.

[41]  M. Peters,et al.  Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins. , 1996, The American journal of pathology.

[42]  J. Kochan,et al.  Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. , 1993, The New England journal of medicine.

[43]  F. Gong,et al.  Thrombin and bradykinin initiate discrete endothelial solute permeability mechanisms. , 1993, The American journal of physiology.

[44]  M. Greaves,et al.  Detection of circulating histamine releasing autoantibodies with functional properties of anti‐IgE in chronic urticaria , 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[45]  A. Kaplan,et al.  Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. , 1988, The Journal of investigative dermatology.

[46]  C. Kennedy,et al.  A serological mediator in chronic idiopathic urticaria—a clinical, immunological and histological evaluation , 1986, The British journal of dermatology.

[47]  F. Ingegnoli,et al.  Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. , 2010, Clinical and experimental rheumatology.

[48]  R. Asero,et al.  Plasma of chronic urticaria patients shows signs of thrombin generation , 2006 .

[49]  R. Paul,et al.  Thrombin-induced force development in vascular endothelial cells: contribution to alteration of permeability mediated by calcium-dependent and -independent pathways. , 2005, Journal of pharmacological sciences.